Drug Approval | March 25, 2022
USFDA approves Janssen’s injectable regimen for HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
Recommendation is based on pivotal data from the phase III POLARIX study
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
MedisimVR is a VR based medical education platform for doctors, nurses & allied health professionals. It aims to make comprehensive Virtual Reality medical simulation more accessible and affordable
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Subscribe To Our Newsletter & Stay Updated
